Biotech PR: Communicating Trial Data to Media and Investors

Biotech and health tech PR communicates clinical, scientific and regulatory developments accurately to reporters, physicians, patients and institutional investors at the same time. It means turning trial data and FDA milestones into language that survives scientific scrutiny and is still clear to a generalist reporter or portfolio manager. The core disciplines are a regulatory-calendar communications plan, one set of facts for media and investors, and a crisis plan ready before a trial hold, a missed endpoint or a complete response letter.

Updated November 2, 2026

On this page: how biotech PR differs from general healthcare PR, the six-part framework, a regulatory calendar, a 12-month plan, health tech milestones, common mistakes, an example from deep tech and FAQs.

A biotech press release gets read by two very different audiences at once. A health reporter wants to know what a Phase 2 readout means for patients. An institutional analyst wants to know what it means for the stock. Both read the same 400 words, and both need an accurate, defensible understanding of the data. That dual audience, plus a regulatory calendar that can move a company's valuation on a single FDA letter, is what separates biotech and health tech PR from healthcare PR in general.

How Is Biotech PR Different From General Healthcare PR?

Virgo's healthcare PR practice covers hospital systems, insurers and consumer health brands. Biotech and health tech PR is a narrower, higher-stakes slice of that world.

Factor What it means for communications

Scope A narrower, higher-stakes slice of healthcare PR

Company stage Often pre-revenue or newly public, with the story resting on data rather than sales

News moments Set by clinical trial phases and FDA decision dates, not by marketing calendars

Audiences Press, physicians, patients and institutional investors, all at the same time

Most important reader On any given day, possibly a sell-side analyst

Risk profile A misstated result can create regulatory, legal and market consequences

What Is a Framework for Biotech Communications?

The framework has six parts.

• Translate the science without simplifying it into something wrong. Work from the underlying data, not a marketing summary. Give journalists context alongside the topline number: the size of the study, the endpoint, the comparison group and the limits of the result.

• Map the regulatory calendar before you need it. The milestones are predictable in timing, so build the plan around them and draft materials for both a positive and a negative outcome.

• Write for the analyst and the reporter in the same document, differently. Coordinate with investor relations from the start so both audiences work from one set of facts. See our investor relations PR guide.

• Build the crisis plan before there is a trial hold. Adverse events, clinical holds and missed endpoints are ordinary parts of development. They become emergencies only when there is no plan. Our crisis communications practice covers this work.

• Treat scientific credibility as a media asset. Peer-reviewed publication, conference presentations and independent researcher citations carry more weight than company claims. Time announcements around these credibility markers.

• Treat health tech as a distinct case. Digital health companies face different milestones, covered below, with the same discipline around accuracy.

Which Regulatory Milestones Shape the Communications Calendar?

• Investigational New Drug (IND) filings

• Enrollment milestones

• Clinical readouts for each trial phase

• PDUFA goal dates, the dates by which the FDA aims to act on an application

• Advisory committee meetings

• Approvals and complete response letters

Each one needs a prepared statement, a spokesperson, a medical and legal review path and a plan for the investor audience. If a milestone date is public, journalists and analysts will be watching it, so silence around it is itself a signal.

What Does a 12-Month Biotech Communications Plan Look Like?

Quarter Focus Typical deliverables

Months 1 to 3 Foundation Messaging framework reviewed by science and legal teams, spokesperson training, reporter and analyst target lists, a data glossary

Months 4 to 6 Credibility Conference abstracts and presentations, scientific advisory board announcements, a byline from the chief medical officer

Months 7 to 9 Readout readiness Scenario statements for positive, mixed and negative results, Q&A documents, investor and media briefing plan

Months 10 to 12 Milestone execution Readout announcement, embargoed briefings where appropriate, follow-up coverage and a results report

Public companies must also follow Regulation FD and the rules on forward-looking statements, so the plan should be built with securities counsel. Our guides to forward-looking statements and the safe harbor and earnings call preparation explain the basics. Companies heading to market should read the IPO quiet period rules and the pre-IPO communications plan.

What Is Different About Health Tech PR?

Digital health companies run on a different calendar. Instead of trial phases, the milestones include:

• FDA clearance or authorization for software that qualifies as a medical device.

• Data privacy and security scrutiny, including how patient data is stored and shared.

• Health system procurement cycles, where a pilot, a contract and a renewal each become a news moment.

• Clinical validation studies that give reporters and buyers evidence beyond a product demo.

The discipline is the same: claims must match the evidence, and every public statement should be reviewed by the people who know the data.

Where Does Biotech PR Stall?

Mistake What goes wrong

Overstating early data A positive trend in a small Phase 1 cohort is not a cure, and reporters and analysts both notice

Treating investor and media messaging as separate tracks When IR and PR use different talking points, the gap becomes the story

Skipping legal and medical review for speed It creates more risk than the delay would have

Going quiet between milestones Without steady credibility markers, the company is invisible when news arrives

Writing for scientists only A generalist reporter cannot use a release that needs a PhD to read

What Can Biotech Learn From Other Deep-Tech Companies?

The challenge of explaining dense science to investors is not unique to biotech. Quantum Art, a trapped-ion quantum computing company, had no public presence and a complex technology. Virgo translated the science into an investor-grade narrative, trained the executives and planned an 18-month announcement calendar. The company raised a $140 million Series A during the engagement. Read the full Quantum Art case study, and see why deep-tech startups struggle to get mainstream coverage.

Frequently asked questions

What is the difference between biotech PR and general healthcare PR?

Biotech PR focuses on clinical-stage and scientific communications for companies whose value depends on trial data and regulatory milestones. General healthcare PR covers providers, payers and consumer health brands.

How does PR work around FDA announcement dates?

Build a communications calendar around known regulatory dates and prepare materials for several outcomes ahead of time. Public companies must also coordinate disclosures with securities counsel.

When should an early-stage biotech start PR?

Build relationships with reporters and analysts well before the first major data readout. The first meaningful coverage often requires a fast, accurate response, and trust takes time to build.

Why does biotech PR have two audiences?

Health reporters and institutional analysts often read the same announcement at the same time. The reporter wants to know what the data means for patients, and the analyst wants to know what it means for the stock.

Who should review biotech press materials before release?

Scientific, medical, legal and, for public companies, investor relations and securities counsel. Every claim should trace back to the underlying data.

Does Virgo PR work with health tech companies?

Yes. Virgo works with healthcare, biotech and health tech companies. If institutional investors are a primary audience, see our investor relations PR guide for how we coordinate media and investor messaging from day one.